Metabolically re-modeling the drug pipeline

Matthew A. Oberhardt, Keren Yizhak, Eytan Ruppin

Research output: Contribution to journalReview articlepeer-review


Costs for drug development have soared, exposing a clear need for new R&D strategies. Systems biology has meanwhile emerged as an attractive vehicle for integrating omics data and other post-genomic technologies into the drug pipeline. One of the emerging areas of computational systems biology is constraint-based modeling (CBM), which uses genome-scale metabolic models (GSMMs) as platforms for integrating and interpreting diverse omics datasets. Here we review current uses of GSMMs in drug discovery, focusing on prediction of novel drug targets and promising lead compounds. We then expand our discussion to prediction of toxicity and selectivity of potential drug targets. We discuss successes as well as limitations of GSMMs in these areas. Finally, we suggest new ways in which GSMMs may contribute to drug discovery, offering our vision of how GSMMs may re-model the drug pipeline in years to come.

Original languageEnglish
Pages (from-to)778-785
Number of pages8
JournalCurrent Opinion in Pharmacology
Issue number5
StatePublished - Oct 2013


Dive into the research topics of 'Metabolically re-modeling the drug pipeline'. Together they form a unique fingerprint.

Cite this